US Bancorp
CRVS icon

US Bancorp’s Corvus Pharmaceuticals CRVS Stock Holding History

US Bancorp’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1K Buy
+1,103
New +$17.6K ﹤0.01% 3193
2022
Q2 		– Sell
-5,153
Closed -$8K – 4097
2022
Q1 		$8K Buy
+5,153
New +$9.43K ﹤0.01% 3443

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

US Bancorp's CRVS Position: Q1 2026 in Review

US Bancorp opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 1,103 shares worth $16.1K. The stake represents ﹤0.01% of the portfolio and ranks #3193 among its holdings. This is a return to the name: US Bancorp previously reported a position in CRVS as recently as Q1 2022.

US Bancorp first reported a position in CRVS in Q1 2022 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • US Bancorp held 1,103 shares of Corvus Pharmaceuticals worth $16.1K as of Q1 2026.
  • Corvus Pharmaceuticals was a new US Bancorp position in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3193 holding.
  • US Bancorp first reported a position in Corvus Pharmaceuticals in Q1 2022 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.